Search by Drug Name or NDC
NDC 00074-0038-28 Orilissa 150 mg/1 Details
Orilissa 150 mg/1
Orilissa is a ORAL TABLET, FILM COATED in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by AbbVie Inc.. The primary component is ELAGOLIX SODIUM.
MedlinePlus Drug Summary
Elagolix is used to manage pain due to endometriosis (a condition in which the type of tissue that lines the uterus [womb] grows in other areas of the body and causes infertility, pain before and during menstrual periods, pain during and after sexual activity, and heavy or irregular bleeding). Elagolix is in a class of medications called gonadotropin-releasing hormone (GnRH) receptor antagonists. It works by decreasing the amount of certain hormones in the body.
Related Packages: 00074-0038-28Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Elagolix
Product Information
| NDC | 00074-0038 |
|---|---|
| Product ID | 0074-0038_0c3c5812-03a4-4ff2-bc62-786488dc4cc4 |
| Associated GPIs | 30090030100320 |
| GCN Sequence Number | 078657 |
| GCN Sequence Number Description | elagolix sodium TABLET 150 MG ORAL |
| HIC3 | P1N |
| HIC3 Description | LHRH(GNRH) ANTAGONIST,PITUITARY SUPPRESSANT AGENTS |
| GCN | 45026 |
| HICL Sequence Number | 045108 |
| HICL Sequence Number Description | ELAGOLIX SODIUM |
| Brand/Generic | Brand |
| Proprietary Name | Orilissa |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | Elagolix |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | TABLET, FILM COATED |
| Route | ORAL |
| Active Ingredient Strength | 150 |
| Active Ingredient Units | mg/1 |
| Substance Name | ELAGOLIX SODIUM |
| Labeler Name | AbbVie Inc. |
| Pharmaceutical Class | Cytochrome P450 2C19 Inhibitors [MoA], Cytochrome P450 3A Inducers [MoA], Decreased GnRH Secretion [PE], Gonadotropin Releasing Hormone Receptor Antagonist [EPC], Gonadotropin Releasing Hormone Receptor Antagonists [MoA], P-Glycoprotein Inhibitors [MoA] |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA210450 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 00074-0038-28 (00074003828)
| NDC Package Code | 0074-0038-28 |
|---|---|
| Billing NDC | 00074003828 |
| Package | 4 BLISTER PACK in 1 CARTON (0074-0038-28) / 7 TABLET, FILM COATED in 1 BLISTER PACK |
| Marketing Start Date | 2018-07-23 |
| NDC Exclude Flag | N |
| Pricing Information | |
| Price Per Unit | 39.8502 |
| Pricing Unit | EA |
| Effective Date | 2024-01-02 |
| NDC Description | ORILISSA 150 MG TABLET |
| Pharmacy Type Indicator | C/I |
| OTC | N |
| Explanation Code | 4 |
| Classification for Rate Setting | B |
| As of Date | 2024-02-21 |
This pricing file, entitled the NADAC (National Average Drug Acquisition
Cost) files, provide
state Medicaid agencies with covered outpatient drug prices by averaging
survey invoice
prices from retail community pharmacies across the United States. These
pharmacies include
independent retail community pharmacies and chain pharmacies. The prices
are updated on a
weekly and monthly basis